Key result
Antiplatelet therapy reduces stroke, MI, or vascular death by ~22% in patients with atherosclerosis.
Why the study?
Antiplatelet therapy with ADP-receptor antagonists has been shown to prevent atherothrombotic events, but comprehensive evidence across various patient populations and regimens needed synthesis.
Does antiplatelet therapy with ADP-receptor antagonists reduce the risk of stroke, MI, or vascular death in patients with atherosclerosis?
Population
135,000 patients with various manifestations of atherosclerosis
Comparison
Antiplatelet agents versus control and different antiplatelet regimens
Design
Meta-analyses and randomized controlled trials including CAPRIE, CURE, CREDO, and ongoing MATCH trial
Authors
Loading...
Supports antiplatelet therapy as standard in atherosclerosis; confirms benefit across broad trial populations.
Does antiplatelet therapy with ADP-receptor antagonists reduce the risk of stroke, MI, or vascular death in patients with atherosclerosis?
Odds Ratio: 0.78
ADP-receptor antagonists, particularly clopidogrel, provide significant reductions in atherothrombotic events across a wide range of patients with atherosclerosis, both as monotherapy and in combination with aspirin.
J. Donald Easton (2003) conducted a review in Atherosclerosis (n=212,000). Antiplatelet therapy and ADP-receptor antagonists vs. Control or different antiplatelet regimens was evaluated on Stroke, myocardial infarction (MI) or vascular death (22% odds reduction). Antiplatelet therapy reduces the combined odds of stroke, myocardial infarction, or vascular death by 22% across a wide range of patients with atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: